Intarcia Therapeutics - Crunchbase Company Profile & Funding

Q: Who invested in Intarcia Therapeutics?

Intarcia Therapeutics has 28 investors including Notable Capital And SharesPost Investment Management.

Q: How much funding has Intarcia Therapeutics raised to date?

Intarcia Therapeutics has raised obfuscated.

Overview

Intarcia Therapeutics

Total Funding

obfuscation

Growth Score

Heat Score

Company Performance Metrics

Score

Trend

About These Metrics

AI Content may contain mistakes and is not legal, financial or investment advice.

Learn more.

Growth Score - The measure of growth based on company activity, operational metrics, and investments

Growth Trend - The change in the growth score over the given time period

Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity

Heat Trend - The change in the heat score over the given time period

See more interactive data and historical milestones on desktop for the best experience

About Intarcia Therapeutics

CB Rank

29037

Intarcia Therapeutics develops therapies for diseases that require long-term chronic treatment.

Acquired by

i2o Therapeutics

Founded

obfuscation

Private

Venture - Series Unknown

Hayward, California, United States

251-500

www.intarcia.com

Biotechnology

Health Care

Health Diagnostics

Medical Device

Personal Health

Funding Rounds

Venture - Series Unknown

OBF

obfuscation

Debt Financing

OBF

obfuscation

Series E

OBF

obfuscation

Key People

Sunita Zalani: Vice President, Global Regulatory Affairs and Quality
Past Role: Eli Lilly, Team Member
Andrew Young: Vice President & Chief Scientific Officer

Details

Legal Name

Intarcia Therapeutics, Inc.

Also Known As

BioMedicines

Operating Status

Active

Company Type

For Profit

About the Company

Intarcia Therapeutics is a biopharmaceutical company that develops therapies for diseases that require long-term chronic treatment. It offers DUROS, a drug delivery platform that stabilizes and delivers therapeutic proteins and peptides.

Intarcia Therapeutics' products include OMEGA DUROS, an interferon delivery device for treating Hepatitis

C and ITCA 650, a delivery device that provides type 2 diabetes patients with long-term steady state dosing of an incretin mimetic therapy. Additionally, it develops programs for treating obesity.

David Franklin, James M. Ahlers, and Thomas Alessi founded BioMedicines in 1997 that became Intarcia Therapeutics in September 2004. Its headquarters is in Hayward in California with an additional office in Mountain View in California.

Phone Number

617-936-2500

Contact Email

busdev@intarcia.com

Hub Tags

Exited Unicorn

Predictions & Insights

Growth Insight

See this Growth Insight

Intarcia Therapeutics is

Lorem

to be growing

Top Contributing Factors

Recently Raised Funding

Growth Prediction

See this Growth Prediction

Top Contributing Factors

Has Achieved Unicorn Status

Products & Services

ITCA 650

A twice-yearly MediciTM implant for type 2 diabetes using exenatide.

Ionic Liquid Platform

A platform transforming injectable biologics and peptides into oral therapies.

Research & Development

Intarcia Therapeutics is

obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated

...

Unlock More with Crunchbase Pro

Full access to financial & funding data on unlimited profiles
Export up to 2k results/month for analysis
Track market signals on competitors, products, and R&D
Preview private company insights and predictions

Financials

Company Funding

Funding Rounds

Investors

Total Funding Amount

obfuscation

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Venture Round - Intarcia Therapeutics	1	obfuscated obfuscation	Notable Capital	Venture - Series Unknown
obfuscated obfuscation	Venture Round - Intarcia Therapeutics	1	obfuscated obfuscation	Notable Capital	Venture - Series Unknown
obfuscated obfuscation	Venture Round - Intarcia Therapeutics	1	obfuscated obfuscation	Notable Capital	Venture - Series Unknown
obfuscated obfuscation	Venture Round - Intarcia Therapeutics	1	obfuscated obfuscation	Notable Capital	Venture - Series Unknown
obfuscated obfuscation	Venture Round - Intarcia Therapeutics	1	obfuscated obfuscation	Notable Capital	Venture - Series Unknown

Funding Rounds

Total Funding Amount

obfuscation

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Venture Round - Intarcia Therapeutics	1	obfuscated obfuscation	Notable Capital	Venture - Series Unknown
obfuscated obfuscation	Venture Round - Intarcia Therapeutics	1	obfuscated obfuscation	Notable Capital	Venture - Series Unknown
obfuscated obfuscation	Venture Round - Intarcia Therapeutics	1	obfuscated obfuscation	Notable Capital	Venture - Series Unknown
obfuscated obfuscation	Venture Round - Intarcia Therapeutics	1	obfuscated obfuscation	Notable Capital	Venture - Series Unknown
obfuscated obfuscation	Venture Round - Intarcia Therapeutics	1	obfuscated obfuscation	Notable Capital	Venture - Series Unknown

Investors

Unlock company funding data, including rounds, dates, amounts, and investors.

Investor Name	Lead Investor	Funding Round	Partners
Notable Capital	Yes	Venture Round - Intarcia Therapeutics	—
Notable Capital	Yes	Venture Round - Intarcia Therapeutics	—
Notable Capital	Yes	Venture Round - Intarcia Therapeutics	—
Notable Capital	Yes	Venture Round - Intarcia Therapeutics	—
Notable Capital	Yes	Venture Round - Intarcia Therapeutics	—

Investments

Investment Breakdown

Number of Acquisitions

Investment Breakdown

Number of Acquisitions

M&A Details

Intarcia Therapeutics

was acquired by

i2o Therapeutics

obfuscation

Transaction Name

Intarcia Therapeutics acquired by i2o Therapeutics

Acquired by

i2o Therapeutics

Announced Date

obfuscation

Market Intelligence

People

View Profiles & Contacts

Headcount

251-500

Employee Profiles

Board Members and Advisors

Contacts

Employee Profiles

Sunita Zalani Vice President, Global Regulatory Affairs and Quality
Andrew Young Vice President & Chief Scientific Officer
Jay Smith CXO- Chief Experience Officer- Head of Customer experience and Outcomes
Dick Ford Executive Director, DUROS® Manufacturing